In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on OncoSec Medical (ONCS), with a price target of $5. The company’s shares opened today at $0.68, close to its 52-week low of $0.54.
McCarthy observed:
“OncoSec announced the company, in collaboration with the Gynecologic Oncology Group (GOG) Foundation, plans to conduct a registration-enabled study evaluating the combination of TAVO (DNA-based IL-12) + Keytruda in recurrent/persistent cervical cancer (study OMS-150).”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -11.6% and a 23.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on OncoSec Medical is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on OncoSec Medical’s latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $7.58 million. In comparison, last year the company had a GAAP net loss of $5.9 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.
